Amarin's PIPE - II Round

Amarin raised a round of funding on October 01, 2009. Investors include Abingworth.

Amarin is a late-stage biopharmaceutical company with a focus on cardiovascular disease. The Companys lead product candidate is AMR101, a prescription grade Omega-3 fatty acid comprising not less than…

Articles about Amarin's PIPE - II Round: